Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2162 entries already.
Entries by Thomas Gabrielczyk
The Best Strategies to Modernise Pharmaceutical Quality Systems
Despite individual regulatory bodies having their own unique set of requirements, for most organisations, the challenges associated with annual product quality reviews (APQR) are largely the same. Issues with fragmented systems and paper-based processes prove increasingly burdensome.
2:1 for new genomic techniques
Following the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs.
Deregulation of new genomic techniques before decision
After the EU Parliament’s Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft law on new genomic techniques.
Amsilk partners with 21st.BIO
AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.
Onera Health raises US$32m in Series C round
Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Spexis sells antibiotics programme to Basilea
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Finnish Enifer Oy secures €12m grant to scale up
Microbial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Mogu Srl raises €11m to scale mycelium technology
Italian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation in US$25m partnership with CARB-X
Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.